Search details
1.
Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists.
Gynecol Oncol
; 184: 43-50, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38277920
2.
An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
Gynecol Oncol
; 182: 188-191, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38493022
3.
Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
Gynecol Oncol
; 183: 53-60, 2024 Apr.
Article
in English
| MEDLINE | ID: mdl-38518528
4.
2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023.
J Low Genit Tract Dis
; 28(1): 3-6, 2024 Jan 01.
Article
in English
| MEDLINE | ID: mdl-38117563
5.
Enduring Consensus Guidelines for Cervical Cancer Screening and Management: Introduction to the Scope and Process.
J Low Genit Tract Dis
; 28(2): 117-123, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38446573
6.
Recommendations for Use of p16/Ki67 Dual Stain for Management of Individuals Testing Positive for Human Papillomavirus.
J Low Genit Tract Dis
; 28(2): 124-130, 2024 Apr 01.
Article
in English
| MEDLINE | ID: mdl-38446575
7.
Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(5): 468-482, 2023 05.
Article
in English
| MEDLINE | ID: mdl-37080223
8.
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
Gynecol Oncol
; 171: 76-82, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36827841
9.
Lifestyle intervention in ovarian cancer enhanced survival (LIVES) study (NRG/GOG0225): Recruitment, retention and baseline characteristics of a randomized trial of diet and physical activity in ovarian cancer survivors.
Gynecol Oncol
; 170: 11-18, 2023 03.
Article
in English
| MEDLINE | ID: mdl-36608382
10.
Moderate to severe distress in half of ovarian cancer patients undergoing treatment highlights a need for more proactive symptom and psychosocial management.
Gynecol Oncol
; 166(3): 503-507, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35778291
11.
Navigating job and cancer demands during treatment: A qualitative study of ovarian cancer patients.
Gynecol Oncol
; 166(3): 481-486, 2022 09.
Article
in English
| MEDLINE | ID: mdl-35902296
12.
Clinical outcomes in patients with COVID-19 and gynecologic cancer: A society of gynecologic oncology COVID-19 and gynecologic cancer registry study.
Gynecol Oncol
; 167(2): 146-151, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36154761
13.
Feasibility, Safety, and Provider Perspectives of Bipolar Electrosurgical Cautery Device for (Opportunistic or Complete) Salpingectomy at the Time of Cesarean Delivery.
Am J Perinatol
; 2022 Jun 21.
Article
in English
| MEDLINE | ID: mdl-35728603
14.
Risk-Based Cervical Consensus Guidelines: Methods to Determine Management if Less Than 5 Years of Data Are Available.
J Low Genit Tract Dis
; 26(3): 195-201, 2022 Jul 01.
Article
in English
| MEDLINE | ID: mdl-35763610
15.
It's time to re-evaluate cervical Cancer screening after age 65.
Gynecol Oncol
; 162(1): 200-202, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33926748
16.
Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Gynecol Oncol
; 160(3): 793-799, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33375989
17.
The financial burden of PARP inhibitors on patients, payors, and financial assistance programs: Who bears the cost?
Gynecol Oncol
; 160(3): 800-804, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33414026
18.
Systematic Next Generation Sequencing is feasible in clinical practice and identifies opportunities for targeted therapy in women with uterine cancer: Results from a prospective cohort study.
Gynecol Oncol
; 163(1): 85-92, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34372972
19.
Beyond Sedlis-A novel histology-specific nomogram for predicting cervical cancer recurrence risk: An NRG/GOG ancillary analysis.
Gynecol Oncol
; 162(3): 532-538, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34217544
20.
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
J Natl Compr Canc Netw
; 19(8): 888-895, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-34416706